###begin article-title 0
###xml 96 104 <span type="species:ncbi:9606">patients</span>
The repeatability of interleukin-6, tumor necrosis factor-alpha, and C-reactive protein in COPD patients over one year
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
Many of the systemic manifestations of chronic obstructive pulmonary disease (COPD) are mediated through increased systemic levels of inflammatory proteins. We assessed the long term repeatability of Interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and C-reactive protein (CRP) over one year and examined the relationships between these systemic markers in COPD.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 202 203 198 199 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</sub>
###xml 24 32 <span type="species:ncbi:9606">patients</span>
Fifty-eight stable COPD patients completed a baseline and one-year visit. Serum IL-6, plasma CRP, and plasma TNF-alpha were measured. Repeatability was expressed by intraclass correlation coefficient (Ri) and the Bland-Altman method. Pearson correlations were used to determine the relationships between the systemic markers at both visits.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
There was moderate repeatability with a very high degree of statistical significance (p </= 0.001) between the two visits for all the systemic biomarkers (IL-6, CRP, and TNF-alpha). CRP was significantly associated with IL-6 at both visits (r = 0.55, p = 0.0001, r = 0.51, p = 0.0002, respectively). There were no other significant associations between the systemic markers at either of the visits.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 120 128 <span type="species:ncbi:9606">patients</span>
Systemic inflammatory biomarkers IL-6, CRP, and TNF-alpha were moderately repeatable over a twelve month period in COPD patients. We have also shown that a robust and repeatable association between IL-6 and CRP exists.
###end p 8
###begin title 9
Introduction
###end title 9
###begin p 10
###xml 123 124 123 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1-copd-4-149">1</xref>
###xml 270 271 270 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2-copd-4-149">2</xref>
###xml 272 273 272 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3-copd-4-149">3</xref>
###xml 306 307 306 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4-copd-4-149">4</xref>
###xml 308 309 308 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5-copd-4-149">5</xref>
###xml 333 334 333 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6-copd-4-149">6</xref>
###xml 352 353 352 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7-copd-4-149">7</xref>
Chronic obstructive pulmonary disease (COPD) is a heterogeneous condition characterized by progressive airway inflammation.1 It is well recognized that systemic manifestations are also a key component of COPD. These include increased levels of inflammation in the blood,2,3 muscle inflammation and wasting,4,5 cardiovascular disease,6 and osteoporosis.7 There is much interest in the use of biomarkers of systemic inflammation in COPD, as these may have possible applications in disease phenotyping, monitoring of disease progression or exacerbations, and measuring the effects of therapeutic interventions.
###end p 10
###begin p 11
###xml 235 236 227 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2-copd-4-149">2</xref>
###xml 237 238 229 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4-copd-4-149">4</xref>
###xml 239 240 231 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8-copd-4-149">8</xref>
###xml 241 243 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12-copd-4-149">12</xref>
###xml 373 374 365 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2-copd-4-149">2</xref>
###xml 375 376 367 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3-copd-4-149">3</xref>
###xml 421 423 413 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13-copd-4-149">13</xref>
###xml 424 426 416 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14-copd-4-149">14</xref>
###xml 476 478 468 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15-copd-4-149">15</xref>
###xml 479 481 471 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16-copd-4-149">16</xref>
###xml 553 555 545 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13-copd-4-149">13</xref>
###xml 642 643 634 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2-copd-4-149">2</xref>
###xml 644 646 636 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17-copd-4-149">17</xref>
###xml 661 662 653 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2-copd-4-149">2</xref>
###xml 683 684 675 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3-copd-4-149">3</xref>
###xml 840 842 832 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18-copd-4-149">18</xref>
###xml 927 928 919 920 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2-copd-4-149">2</xref>
###xml 929 930 921 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3-copd-4-149">3</xref>
###xml 931 933 923 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19-copd-4-149">19</xref>
###xml 934 936 926 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20-copd-4-149">20</xref>
###xml 305 313 <span type="species:ncbi:9606">patients</span>
###xml 489 497 <span type="species:ncbi:9606">patients</span>
###xml 918 926 <span type="species:ncbi:9606">patients</span>
It is believed that many of the systemic manifestations of COPD are mediated through increased systemic levels of inflammatory proteins such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha) and C-reactive protein (CRP).2-4,8-12 CRP is a commonly used biomarker of systemic inflammation in patients with COPD. Plasma CRP levels are increased in COPD patients2,3 and are associated with increased mortality.13,14 CRP levels are predictive of cardiovascular risk,15,16 and in patients with COPD also independently predict death due to COPD.13 CRP is also related to other important clinical outcomes including exercise tolerance,2,17 health status,2 and muscle strength.3 CRP is regulated by IL-6, as this cytokine can initiate an acute phase response through the induction of acute phase proteins including CRP in hepatocytes.18 Consequently, it has been shown that IL-6 and CRP levels correlate in COPD patients.2,3,19,20
###end p 11
###begin p 12
###xml 107 108 103 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9-copd-4-149">9</xref>
###xml 109 111 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21-copd-4-149">21</xref>
###xml 112 114 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22-copd-4-149">22</xref>
###xml 237 238 229 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4-copd-4-149">4</xref>
###xml 239 240 231 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8-copd-4-149">8</xref>
###xml 241 243 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11-copd-4-149">11</xref>
###xml 244 246 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12-copd-4-149">12</xref>
###xml 247 249 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21-copd-4-149">21</xref>
###xml 324 325 312 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3-copd-4-149">3</xref>
###xml 326 328 314 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19-copd-4-149">19</xref>
###xml 329 331 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23-copd-4-149">23</xref>
###xml 340 341 328 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3-copd-4-149">3</xref>
###xml 393 394 381 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2-copd-4-149">2</xref>
###xml 228 236 <span type="species:ncbi:9606">patients</span>
TNF-alpha has been shown to play a central role in the muscle wasting and weight loss seen in COPD patients9,21,22 and several studies have demonstrated increased levels of TNF-alpha and its receptors in the circulation of COPD patients.4,8,11,12,21 There is some evidence that TNF-alpha levels are related to levels of IL-63,19,23 and CRP,3 although this has not been reported in all studies.2
###end p 12
###begin p 13
###xml 64 66 64 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17-copd-4-149">17</xref>
###xml 205 207 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24-copd-4-149">24</xref>
CRP has previously been shown in a study by Pinto and colleagues17 to be repeatable over a 17 month period and even more recently both IL-6 and CRP have been shown to be repeatable over a six month period.24 However longer term studies of the repeatability of IL-6 and TNF-alpha are lacking. The repeatability of systemic biomarkers is an important issue, as those with increased variability will have less utility in clinical practice or research. Studies analyzing longer term repeatability are needed if systemic biomarkers are going to be used in long term observational studies or clinical trials of therapeutic interventions.
###end p 13
###begin p 14
###xml 144 152 <span type="species:ncbi:9606">patients</span>
The main aims of this study were to 1) assess the long term repeatability of systemic biomarkers of inflammation (CRP, TNF-alpha, IL-6) in COPD patients over one year, 2) to examine the relationships between these systemic markers and confirm the results of previous studies in this area.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
Subjects
###end title 16
###begin p 17
###xml 500 501 500 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1-copd-4-149">1</xref>
###xml 19 27 <span type="species:ncbi:9606">patients</span>
###xml 176 184 <span type="species:ncbi:9606">patients</span>
###xml 245 253 <span type="species:ncbi:9606">patients</span>
###xml 676 684 <span type="species:ncbi:9606">Patients</span>
Ninety-four stable patients were initially recruited into this single centre study from primary care by media advertising to the study at baseline (2004-2005), however only 58 patients returned for their follow up assessment (2005-2006). The 36 patients were lost to follow up as they either had withdrawn their consent or had not returned for their visit within the one-year timeframe. COPD was diagnosed according to current Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines,1 based on a smoking history of at least 10 pack-years with typical symptoms (one or more of productive cough, breathlessness, and wheeze) and evidence of airflow obstruction. Patients with a clinical history of asthma, alpha-1-antitrypsin deficiency, an exacerbation or any change in their COPD therapy within four weeks of the study at the baseline and the one-year visit, or a history of lung cancer were excluded. Written informed consent was obtained and the local ethics committee approved the study.
###end p 17
###begin title 18
Study design
###end title 18
###begin p 19
Spirometry, sputum induction, and peripheral blood sampling were performed at the baseline visit and then repeated one year later. Sputum differential cell counts were performed and IL-8 was measured in the sputum supernatant to characterize airway inflammatory biomarkers. Serum IL-6, plasma CRP, and plasma TNF-alpha were measured at both visits as biomarkers of systemic inflammation. Height was measured to the nearest cm and weight to the nearest 100 gm. Body mass index (BMI) was calculated as weight in kg divided by squared height in meters.
###end p 19
###begin title 20
Spirometry
###end title 20
###begin p 21
###xml 184 185 184 185 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
Maximum expiratory flow volume measurements were performed using the spirometry system on the MasterScreen (Jaeger GmbH, Wurzburg, Germany). Forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) readings were performed in triplicate. Spirometry during sputum induction was performed with a Vitalograph spirometer (Vitalograph, Buckinghamshire, UK). The equipment was calibrated daily according to the manufacturer's instructions.
###end p 21
###begin title 22
Plasma and serum assays
###end title 22
###begin p 23
###xml 505 513 <span type="species:ncbi:9606">patients</span>
Plasma and serum were obtained from peripheral blood samples by centrifugation for 15 minutes, at 1500 g and at 4 degreesC or ambient temperature, respectively. Plasma and serum samples were stored at -80 degreesC until analysis. Plasma TNF-alpha and serum IL-6 was measured by high sensitivity ELISA (Quantikine, R&D Systems Europe, Oxon, UK) with a lower limit of detection of 0.5 pg/ml and 0.156 pg/ml respectively. Serum was used for the IL-6 assay as there was insufficient plasma available from all patients. Plasma CRP was measured by high sensitivity particle-enhanced immunonephelometry (Cardiophase; BN systems, Dade Behring, Newark, NJ, USA) with a lower limit of detection of 0.175 mg/L.
###end p 23
###begin title 24
Statistical analysis
###end title 24
###begin p 25
The Kolmogorov - Smirnov test determined normality of the data and nonparametric data were natural log transformed. Naturally log-transformed data was therefore used for IL-6, CRP, and TNF-alpha for our anlaysis.
###end p 25
###begin p 26
###xml 180 181 180 181 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</sub>
###xml 301 302 301 302 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</sub>
###xml 683 685 683 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30-copd-4-149">30</xref>
Paired t test was performed to determine the mean differences between the baseline and one-year visit. Repeatability was expressed as an intraclass correlation coefficient (ICC) [Ri = between-subject variance/(within- + between- subject variance)]. P < 0.05 was considered statistically significant. Ri values of 0 to 0.2 are usually interpreted to indicate slight repeatability, 0.21 to 0.40 to indicate fair repeatability, 0.41 to 0.60 to indicate moderate repeatability, 0.61 to 0.8 to indicate good repeatability, and 0.81 to 1.00 to indicate very good repeatability. Graphical representation of repeatability between the two visits were reported using the Bland - Altman method.30 The limits of agreement are expressed as +/- 2 standard deviations (SD) of the mean of differences betweeen the two measurements within which 95% of the repeated measures are expected to lie and for our naturally log-transformed data the limits of agreement were antilogged to express the fold changes expected over a one-year period.
###end p 26
###begin p 27
Pearson correlations were used to determine the relationships between the systemic markers at both the baseline and one-year visit. Statistical analyses were performed using SPSS (SPSS Inc., Chicago, IL, USA) and GraphPad (GraphPad Software, Inc., La Jolla, CA, USA) software.
###end p 27
###begin p 28
###xml 70 72 70 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25-copd-4-149">25</xref>
###xml 73 75 73 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29-copd-4-149">29</xref>
###xml 88 90 88 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24-copd-4-149">24</xref>
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17-copd-4-149">17</xref>
###xml 143 151 <span type="species:ncbi:9606">patients</span>
###xml 248 256 <span type="species:ncbi:9606">patients</span>
Previous publications studying the repeatability of sputum biomarkers,25-29 plasma IL-6,24 and CRP17 used varying sample sizes from 10-88 COPD patients. Thus, we enrolled 94 subjects, and considered that the matched data from the returning 58 COPD patients who had both baseline and one-year measurements was an adequate sample size for this study.
###end p 28
###begin title 29
Results
###end title 29
###begin p 30
###xml 151 158 151 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1-copd-4-149">Table 1</xref>
###xml 179 180 179 180 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 269 277 269 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1-copd-4-149">Figure 1</xref>
###xml 331 338 331 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2-copd-4-149">Table 2</xref>
###xml 58 66 <span type="species:ncbi:9606">patients</span>
###xml 99 107 <span type="species:ncbi:9606">patients</span>
###xml 126 134 <span type="species:ncbi:9606">patients</span>
###xml 465 473 <span type="species:ncbi:9606">patients</span>
The study population was composed of 58 subjects, with 40 patients categorized as GOLD stage 2, 15 patients as stage 3, and 3 patients at stage 4 (see Table 1 for demography). FEV1 percent predicted did not change over the one-year period (mean 56.7 vs 57.5, p = 0.1) (Figure 1) and neither did BMI (mean 27.45 vs 27.31, p = 0.4). Table 2 shows the baseline and one-year values for other pulmonary function tests. Peripheral blood samples were obtained from all 58 patients at both visits.
###end p 30
###begin title 31
Repeatability of systemic biomarkers
###end title 31
###begin p 32
###xml 0 7 0 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t3-copd-4-149">Table 3</xref>
Table 3 summarizes the measurements of the systemic inflammatory biomarkers and BMI at the baseline and one-year visit. Using paired T tests there was no statistically significant change in these measurements between both visits (p > 0.05 for all comparisons).
###end p 32
###begin p 33
###xml 314 322 308 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2-copd-4-149">Figure 2</xref>
Using ICC analysis, there was moderate agreement with a very high degree of statistical significance (p </= 0.001) between the two visits for all the systemic biomarkers (IL-6, CRP, and TNF-alpha). Graphical representations of the repeatability of systemic biomarkers using the Bland - Altman methods are shown in Figure 2. These plots indicate moderate reproducibility, as the mean differences of the repeated measurements lie close to zero and all values are randomly scattered around the mean difference with the majority of values lying within the limits of agreement (+/-2 SD). Antilogging the limits for IL-6, CRP, and TNF-alpha show that 95% of cases for the one-year measurement will have at least a 3.8-, 5.2-, and 2.8-fold change from the baseline measurement, respectively.
###end p 33
###begin title 34
Relationships between systemic biomarkers
###end title 34
###begin p 35
###xml 139 149 139 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3a-copd-4-149">Figures 3a</xref>
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3b-copd-4-149">3b</xref>
###xml 255 264 255 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t4a-copd-4-149">Tables 4a</xref>
###xml 266 268 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t4b-copd-4-149">4b</xref>
CRP was significantly associated with IL-6 at the baseline and one-year visits (r = 0.55, p = 0.0001, r = 0.51, p = 0.0002, respectively) (Figures 3a, 3b). There were no other significant associations between the systemic markers at either of the visits (Tables 4a, 4b).
###end p 35
###begin title 36
Discussion
###end title 36
###begin p 37
###xml 302 303 298 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2-copd-4-149">2</xref>
###xml 304 305 300 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3-copd-4-149">3</xref>
###xml 306 308 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19-copd-4-149">19</xref>
###xml 309 311 305 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20-copd-4-149">20</xref>
###xml 401 402 393 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3-copd-4-149">3</xref>
###xml 403 405 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19-copd-4-149">19</xref>
###xml 406 408 398 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23-copd-4-149">23</xref>
The main novelty of this study is the repeatability of systemic biomarkers in a moderate to severe COPD population over one-year. IL-6, CRP, and TNF-alpha showed moderate repeatability over one year. We also found a moderate association between CRP and IL-6, confirming the results of previous studies,2,3,19,20 but no association between these proteins and TNF-alpha, in contrast to previous reports.3,19,23
###end p 37
###begin p 38
###xml 402 403 402 403 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</sub>
###xml 77 85 <span type="species:ncbi:9606">patients</span>
###xml 641 649 <span type="species:ncbi:9606">patients</span>
The repeatability of systemic inflammatory biomarkers over 12 months in COPD patients was analyzed by three statistical methods; first, we observed no significant changes in group mean values for any of the measurements. Second, using ICC, which is a recognized method for assessing the repeatability of measurements, we observed moderate levels of agreement for systemic inflammatory markers, as the Ri values were >/=0.5. Third, we also present Bland - Altman plots to view the repeatability of data from individual subjects. To our knowledge, this is the first study to compare the long term reproducibility of IL-6 and TNF-alpha in COPD patients, and we demonstrate moderate repeatability for these systemic biomarkers over a 12 month period.
###end p 38
###begin p 39
###xml 78 80 78 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17-copd-4-149">17</xref>
It has previously been shown that CRP did not change over a 17 month interval,17 but we are not aware of any similar information concerning IL-6 and TNF-alpha. The assessments of repeatability in our study can be used in the following ways; the within-subject SDs can be used to aid the statistical powering of clinical trials with pharmacological interventions and the Bland-Altman plots show the variation that could be expected for individual measurements in clinical practice.
###end p 39
###begin p 40
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15-copd-4-149">15</xref>
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16-copd-4-149">16</xref>
###xml 425 426 425 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2-copd-4-149">2</xref>
###xml 427 428 427 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3-copd-4-149">3</xref>
###xml 429 431 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17-copd-4-149">17</xref>
###xml 499 501 499 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18-copd-4-149">18</xref>
###xml 553 554 553 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2-copd-4-149">2</xref>
###xml 555 556 555 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3-copd-4-149">3</xref>
###xml 557 558 557 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6-copd-4-149">6</xref>
###xml 559 561 559 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19-copd-4-149">19</xref>
###xml 702 703 698 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4-copd-4-149">4</xref>
###xml 704 706 700 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31-copd-4-149">31</xref>
###xml 707 709 703 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b32-copd-4-149">32</xref>
###xml 544 552 <span type="species:ncbi:9606">patients</span>
###xml 634 642 <span type="species:ncbi:9606">patients</span>
The systemic biomarkers that we investigated all appear to be related to pathophysiological processes in COPD; CRP is related to cardiovascular risk15,16 and has been shown to be associated with many other important clinical outcomes of COPD. For example previous studies have been shown CRP to be related to the symptom domain of St George's Respiratory Questionnaire (SGRQ), impaired energy metabolism, and muscle strength.2,3,17 IL-6 is known as a powerful promoter of CRP production in the liver18 and is associated with CRP levels in COPD patients,2,3,6,19 whilst TNF-alpha and its receptors are increased in the muscles of COPD patients thus implicating it in conditions such as cachexia in COPD.4,31,32
###end p 40
###begin p 41
###xml 109 117 <span type="species:ncbi:9606">patients</span>
###xml 329 337 <span type="species:ncbi:9606">patients</span>
The present study confirms that the link between IL-6 and CRP exists in our group of moderate to severe COPD patients and that it is a robust relationship that does not change over one year. The moderate association (r = 0.51-0.55) on two occasions adds confidence to our interpretation that IL-6 promotes CRP production in COPD patients.
###end p 41
###begin p 42
###xml 187 188 179 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3-copd-4-149">3</xref>
###xml 189 191 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19-copd-4-149">19</xref>
###xml 221 222 209 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3-copd-4-149">3</xref>
###xml 574 576 550 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33-copd-4-149">33</xref>
###xml 577 579 553 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34-copd-4-149">34</xref>
###xml 690 692 662 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33-copd-4-149">33</xref>
###xml 693 695 665 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34-copd-4-149">34</xref>
###xml 776 778 748 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11-copd-4-149">11</xref>
###xml 779 781 751 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21-copd-4-149">21</xref>
###xml 231 239 <span type="species:ncbi:9606">patients</span>
###xml 767 775 <span type="species:ncbi:9606">patients</span>
###xml 857 865 <span type="species:ncbi:9606">patients</span>
The finding that neither IL-6 nor CRP was related to the TNF-alpha is in contrast to two previous studies that showed a relationship, albeit a weak correlation, between TNF-alpha and IL-63,19 and TNF-alpha and CRP existed3 in COPD patients. One methodological explanation for the lack of correlation in the current study could be due to the short half life of TNF-alpha compared to IL-6 or CRP. TNF-alpha has a short half-life of a few minutes and is also difficult to detect because it forms complexes with soluble TNF-alpha receptors (sTNF-R) and has high renal clearance.33,34 Circulating sTNF-R may be a more sensitive marker of TNF-alpha activation as they have slower renal clearance.33,34 Increased levels of these soluble receptors have been detected in COPD patients.11,21 In addition the current study population consisted mainly of moderate COPD patients and a different relationship to TNF-alpha may have been observed in a population consisting of a range of disease severities.
###end p 42
###begin p 43
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35-copd-4-149">35</xref>
###xml 213 215 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36-copd-4-149">36</xref>
###xml 338 339 338 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5-copd-4-149">5</xref>
###xml 593 594 589 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2-copd-4-149">2</xref>
###xml 595 596 591 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4-copd-4-149">4</xref>
###xml 597 599 593 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17-copd-4-149">17</xref>
###xml 658 659 654 655 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 805 807 801 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37-copd-4-149">37</xref>
###xml 1122 1123 1114 1115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2-copd-4-149">2</xref>
###xml 70 78 <span type="species:ncbi:9606">patients</span>
###xml 641 649 <span type="species:ncbi:9606">patients</span>
###xml 817 825 <span type="species:ncbi:9606">patients</span>
###xml 908 916 <span type="species:ncbi:9606">patients</span>
###xml 990 998 <span type="species:ncbi:9606">patients</span>
###xml 1056 1064 <span type="species:ncbi:9606">patients</span>
BMI is recognized as an important tool in defining phenotypes of COPD patients and a reduced BMI has been shown to be an independent risk factor for mortality in COPD and to be associated with disease severity.35,36 Increased skeletal muscle apoptosis have also been shown to be associated with a lower BMI and reduced exercise tolerance.5 In our study BMI was not related to circulating levels of IL-6, CRP, and TNF-alpha. This suggests that body mass loss may not be caused through systemic inflammation. However, there are studies that have shown CRP and BMI to be associated to each other.2,4,17 These findings were found in severe COPD patients with FEV1 < 40% in comparison to the current study population comprised mainly of moderate disease. Although, in one recent study by Karadag and colleagues37 moderate patients were grouped into low BMI and normal-to-high BMI and they showed that the low BMI patients had higher levels of CRP and TNF-alpha. Conversely, in our population of patients we did not observe significant weight loss in individual patients over one-year, with our mean values of BMI being >25 kg/m2 at both visits. This perhaps could also account for the lack of correlation observed between change in BMI and inflammatory biomarkers.
###end p 43
###begin p 44
###xml 88 89 84 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4-copd-4-149">4</xref>
###xml 90 91 86 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9-copd-4-149">9</xref>
###xml 184 185 180 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4-copd-4-149">4</xref>
###xml 525 526 517 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8-copd-4-149">8</xref>
###xml 692 694 684 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38-copd-4-149">38</xref>
###xml 408 416 <span type="species:ncbi:9606">patients</span>
###xml 516 524 <span type="species:ncbi:9606">patients</span>
TNF-alpha and IL-6 levels have been shown to be increased in weight losing COPD patients4,9 However the present study does not support this finding. In the study by Eid and colleagues,4 weight loss characterized by reduced fat free mass (FFM) and skeletal muscle mass was associated with increased systemic inflammatory response. They showed that TNF-alpha, sTNF-R, and IL-6 were inversely related to FFM in patients with normal BMI. Another study also showed that CRP was inversely related to FFM in hypermetabolic patients.8 FFM appears to be a better marker of weight loss compared to BMI, particularly since FFM has been shown to be a predictor of mortality in the presence of normal BMI.38 BMI has the advantage of being easy to measure but is a limited value as it does not represent changes in body composition or reflect skeletal muscle depletion.
###end p 44
###begin p 45
###xml 423 425 419 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b39-copd-4-149">39</xref>
###xml 1346 1348 1342 1344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b40-copd-4-149">40</xref>
###xml 1376 1378 1372 1374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20-copd-4-149">20</xref>
###xml 532 539 <span type="species:ncbi:9606">patient</span>
###xml 723 731 <span type="species:ncbi:9606">patients</span>
###xml 1144 1152 <span type="species:ncbi:9606">patients</span>
The limitations of our study are: (a) we did not measure many other systemic biomarkers that may be of interest in COPD due to limited resources and therefore we decided to measure IL-6, CRP, and TNF-alpha because of their potential role in the pathopyhysiology of COPD; (b) we measured our samples only once at enrollment and at 12 months. It would have been of interest to have performed "serial sampling"; a recent study39 using 11 visits performed over a one-month interval to assess inflammatory biomarkers suggests that intra-patient variability is reduced with the use of a "rolling mean" of serial samples; (c) our population was composed of mainly moderate-to-severe disease, and the inclusion of more very severe patients would have been of interest especially to examine the repeatability by different GOLD severities; (d) we did not capture any clinical changes such as exacerbation within in the one-year interval excluding the four-week interval leading up to their study visit which may have influenced our results; (e) we were unable to perform analysis related to changes in therapeutic regime as we were limited by numbers of patients that had actually had a change in their medications such as stopping/starting inhaled corticosteroids (ICS) by the one-year visit. Although, it has recently been confirmed by Sin and colleagues40 and Kuniaski and colleagues20 that ICS use does not affect IL-6 and CRP levels measured; and (f) we did not relate our findings to other clinical parameters of COPD such as partial pressure of oxygen in arterial blood, exercise tolerance, and health status over an one-year interval.
###end p 45
###begin p 46
###xml 135 143 <span type="species:ncbi:9606">patients</span>
In conclusion, the systemic inflammatory biomarkers IL-6, CRP, and TNF-alpha were moderately repeatable over a 12 month period in COPD patients. We have also shown that a robust and repeatable association between IL-6 and CRP exists. However, there was a lack of correlation of TNF-alpha to IL-6 or CRP, possibly due to the instability of TNF-alpha, or perhaps because TNF-alpha genuinely plays a different role to IL-6 and CRP in the pathophysiology of COPD.
###end p 46
###begin p 47
###xml 0 10 0 10 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Disclosure</bold>
Disclosure
###end p 47
###begin p 48
The authors report no conflicts of interest in this work.
###end p 48
###begin title 49
References
###end title 49
###begin article-title 50
Raised CRP levels mark metabolic and functional impairment in advanced COPD
###end article-title 50
###begin article-title 51
Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects
###end article-title 51
###begin article-title 52
Inflammatory response and body composition in chronic obstructive pulmonary disease
###end article-title 52
###begin article-title 53
Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease
###end article-title 53
###begin article-title 54
###xml 8 16 <span type="species:ncbi:9606">patients</span>
Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease
###end article-title 54
###begin article-title 55
###xml 34 42 <span type="species:ncbi:9606">patients</span>
The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease: a cross sectional study
###end article-title 55
###begin article-title 56
###xml 119 127 <span type="species:ncbi:9606">patients</span>
Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease
###end article-title 56
###begin article-title 57
###xml 82 90 <span type="species:ncbi:9606">patients</span>
Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients
###end article-title 57
###begin article-title 58
Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis
###end article-title 58
###begin article-title 59
###xml 22 30 <span type="species:ncbi:9606">patients</span>
Circulating leptin in patients with chronic obstructive pulmonary disease
###end article-title 59
###begin article-title 60
Systemic inflammation in chronic obstructive pulmonary disease and asthma: Similarities and differences
###end article-title 60
###begin article-title 61
C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease
###end article-title 61
###begin article-title 62
C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease
###end article-title 62
###begin article-title 63
Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association
###end article-title 63
###begin article-title 64
Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events
###end article-title 64
###begin article-title 65
###xml 22 30 <span type="species:ncbi:9606">patients</span>
C-reactive protein in patients with COPD, control smokers and non-smokers
###end article-title 65
###begin article-title 66
The biology of interleukin-6
###end article-title 66
###begin article-title 67
The relationship between inflammatory markers and disability in chronic obstructive pulmonary disease (COPD)
###end article-title 67
###begin article-title 68
Exhaled nitric oxide, systemic inflammation, and the spirometric response to inhaled fluticasone propionate in severe chronic obstructive pulmonary disease: a prospective study
###end article-title 68
###begin article-title 69
###xml 103 111 <span type="species:ncbi:9606">patients</span>
The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease
###end article-title 69
###begin article-title 70
Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease
###end article-title 70
###begin article-title 71
Biomarkers of systemic inflammation in stable and exacerbation phases of COPD
###end article-title 71
###begin article-title 72
###xml 80 88 <span type="species:ncbi:9606">patients</span>
Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin
###end article-title 72
###begin article-title 73
Long-term repeatability of induced sputum cells and inflammatory markers in stable, moderately severe COPD
###end article-title 73
###begin article-title 74
Eosinophilic inflammation in stable chronic obstructive pulmonary disease. Relationship with neutrophils and airway function
###end article-title 74
###begin article-title 75
Induced sputum and other outcome measures in chronic obstructive pulmonary disease: safety and repeatability
###end article-title 75
###begin article-title 76
###xml 67 75 <span type="species:ncbi:9606">patients</span>
Repeatability of inflammatory parameters in induced sputum of COPD patients
###end article-title 76
###begin article-title 77
The cellular composition of induced sputum in chronic obstructive pulmonary disease
###end article-title 77
###begin article-title 78
Statistical methods for assessing agreement between two methods of clinical measurement
###end article-title 78
###begin article-title 79
Chronic Obstructive Pulmonary Disease, inflammation and co-morbidity - a common inflammatory phenotype?
###end article-title 79
###begin article-title 80
Tumor necrosis factor-alpha and muscle wasting: a cellular perspective
###end article-title 80
###begin article-title 81
Tumor necrosis factor: function, release and clearance
###end article-title 81
###begin article-title 82
Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis
###end article-title 82
###begin article-title 83
Prognostic value of nutritional status in chronic obstructive pulmonary disease
###end article-title 83
###begin article-title 84
Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease
###end article-title 84
###begin article-title 85
The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease
###end article-title 85
###begin article-title 86
###xml 48 56 <span type="species:ncbi:9606">patients</span>
Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study
###end article-title 86
###begin article-title 87
###xml 52 60 <span type="species:ncbi:9606">patients</span>
###xml 101 108 <span type="species:ncbi:9606">patient</span>
###xml 119 126 <span type="species:ncbi:9606">patient</span>
Inter-relationships between inflammatory markers in patients with stable COPD with bronchitis: intra-patient and inter-patient variability
###end article-title 87
###begin article-title 88
The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease
###end article-title 88
###begin p 89
###xml 3 4 3 4 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 26 34 <span type="species:ncbi:9606">patients</span>
FEV1 % predicted for each patients at the baseline and year 1 visit.
###end p 89
###begin p 90
###xml 23 24 23 24 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</bold>
###xml 32 33 32 33 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</bold>
###xml 43 44 43 44 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</bold>
Bland-Altman plots for a) IL-6, b) CRP and c)TNFalpha collected with a one year interval. The dotted lines represent the mean difference +/- 2 SD.
###end p 90
###begin p 91
###xml 0 14 0 14 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Abbreviations:</bold>
Abbreviations: CRP, C-reactive protein; IL, interleukin; TNFalpha, tumor necrosis factor-alpha.
###end p 91
###begin p 92
The relationship between CRP and IL-6 at the baseline visit.
###end p 92
###begin p 93
###xml 0 14 0 14 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Abbreviations:</bold>
Abbreviations: CRP, C-reactive protein; IL-6, interleukin-6.
###end p 93
###begin p 94
The relationship between CRP and IL-6 at the one-year visit.
###end p 94
###begin p 95
###xml 0 14 0 14 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Abbreviations:</bold>
Abbreviations: CRP, C-reactive protein; IL-6, interleukin-6.
###end p 95
###begin p 96
###xml 38 46 <span type="species:ncbi:9606">patients</span>
Baseline characteristics of the study patients
###end p 96
###begin p 97
###xml 0 14 0 14 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Abbreviations:</bold>
###xml 63 64 63 64 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; IQR, interquartile range; SD, standard deviation.
###end p 97
###begin p 98
###xml 0 6 0 6 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Notes:</bold>
###xml 86 94 <span type="species:ncbi:9606">patients</span>
Notes: Lung function measurements were standardized for age and gender. There were no patients on oral corticosteroids. Results presented as mean (SD) or median (IQR).
###end p 98
###begin p 99
Pulmonary function at the baseline visit and one-year visit
###end p 99
###begin p 100
###xml 0 14 0 14 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Abbreviations:</bold>
###xml 43 44 43 44 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
Abbreviations: CI, confidence interval; FEV1, forced expiratory volume in one second; FRC, functional residual capacity; IC, inspiratory capacity; KCO, carbon monoxide diffusion factor; Raw, airways resistance; RV, residual volume; SD, standard deviation; sGaw, specific airways conductance; TLC, total lung capacity.
###end p 100
###begin p 101
###xml 0 6 0 6 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Notes:</bold>
###xml 86 94 <span type="species:ncbi:9606">patients</span>
Notes: Lung function measurements were standardized for age and gender. There were no patients on oral corticosteroids. Results presented as mean (SD) or geometric mean (95% CI).
###end p 101
###begin p 102
Repeatability of systemic measurements over the one year interval
###end p 102
###begin p 103
###xml 0 14 0 14 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Abbreviations:</bold>
Abbreviations: CRP, C-reactive protein; IL-6, interleukin-6; TNF-alpha, tumor necrosis factor-alpha.
###end p 103
###begin p 104
###xml 0 5 0 5 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Note:</bold>
Note: Data presented as geometric mean (95% CI).
###end p 104
###begin p 105
Relationships between systemic inflammatory biomarkers and BMI at the baseline visit
###end p 105
###begin p 106
###xml 0 14 0 14 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Abbreviations:</bold>
Abbreviations: BMI, body mass index; CRP, C-reactive protein; IL-6, interleukin-6; TNF-alpha, tumor necrosis factor-alpha.
###end p 106
###begin p 107
Relationships between systemic inflammatory biomarkers and BMI at the one-year visit
###end p 107
###begin p 108
###xml 0 14 0 14 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Abbreviations:</bold>
Abbreviations: BMI, body mass index; CRP, C-reactive protein; IL-6, interleukin-6; TNF-alpha, tumor necrosis factor-alpha.
###end p 108

